CA Patent

CA3196482A1 — Jak inhibitors having a specific particle size distribution

Assigned to Elanco US Inc · Expires 2022-04-28 · 4y expired

What this patent protects

The present disclosure provides compositions of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile having a specific acceptance value and/or particle size distribution, pharmaceutical compositions comprising the same, meth…

USPTO Abstract

The present disclosure provides compositions of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile having a specific acceptance value and/or particle size distribution, pharmaceutical compositions comprising the same, methods of using the same, and processes for making the same.

Drugs covered by this patent

Patent Metadata

Patent number
CA3196482A1
Jurisdiction
CA
Classification
—
Expires
2022-04-28
Drug substance claim
No
Drug product claim
No
Assignee
Elanco US Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.